Advertisement
Organisation › Details
Advanced Accelerator Applications (AAA) (Group)
Advanced Accelerator Applications (AAA) is a European pharmaceutical company founded in 2002 to develop innovative diagnostic and therapeutic products. AAA's main focus is in the field of Molecular Imaging and targeted, individualized therapy for the management of patients with serious conditions (Personalized Medicine). AAA currently has 17 production and R&D facilities able to manufacture both diagnostics and therapeutic MNM products, and has over 270 employees in 10 countries (France, Italy, Germany, Switzerland, Spain, Poland, Portugal, Israel, U.S., Canada). In 2013 AAA is expecting to reach revenues of €56.6 million (+27% vs. 2012) and EBITDA of €14 million (+49% vs. 2012). *
Start | 2002-01-01 splitoff | |
End | 2018-01-22 acquired | |
Group | Novartis (Group) | |
Today | Novartis (Group) | |
Predecessor | CERN (European Organisation for Nuclear Research) | |
Successor | Novartis (Group) | |
Industry | RADIOPHARMACEUTICAL (RPT) | |
Person | Buono, Stefano (Advanced Accelerator Applications 201402 CEO) | |
Person 2 | Wicki, Andreas (HBM Healthcare Investments 201402 CEO) | |
Region | Rhône-Alpes (region) [before 2015] | |
Country | France | |
Street | 20 Rue Diesel | |
City | 01630 Saint-Genis-Pouilly | |
Tel | +33-4-5099-3070 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | D: 101 to 500 (2014-02-17) |
Currency | EUR | |
Annual sales | 109,000,000 (sales (2016) 2016-12-31) | |
* Document for »About Section«: | ||
Record changed: 2024-02-12 |
Advertisement
More documents for Novartis (Group)
- [1] Mediar Therapeutics Inc.. (3/15/23). "Press Release: Mediar Therapeutics Announces $105 Million Financing to Advance Portfolio of First-in-Class Fibrosis Therapies". Cambridge, MA....
- [2] Ariceum Therapeutics GmbH. (2/1/23). "Press Release: Ariceum Therapeutics Appoints Radioligand Expert, Germo Gericke, M.D., as Chief Medical Officer". Berlin....
- [3] EuropaBio. (9/3/20). "Press Release: Novartis’s Andrew Topen Appointed as New Chairman of EuropaBio"....
- [4] Voluntis S.A.. (3/4/20). "Press Release: Voluntis Announces Its New Strategic Roadmap. Strategic Prioritization of the Oncology Business". Cambridge, MA & Paris....
- [5] Voluntis S.A.. (12/18/19). "Press Release: Voluntis Announces New Pharma Collaboration in Oncology". Cambridge, MA & Paris....
- [6] Novartis AG. (8/30/19). "Press Release: Novartis Ofatumumab Demonstrates Superiority versus Aubagio in Two Head-to-head Phase III Multiple Sclerosis Studies". Basel....
- [7] Sanofi S.A.. (6/7/19). "Press Release: Paul Hudson to Succeed Olivier Brandicourt as Chief Executive Officer". Paris....
- [8] Novartis AG. (5/24/19). "Press Release: FDA Approves Novartis Piqray - the First and Only Treatment Specifically for Patients with a PIK3CA Mutation in HR+/HER2- Advanced Breast Cancer". Basel....
- [9] Sanofi S.A.. (2/12/19). "Press Release: Sanofi Appoints Ameet Nathwani Chief Digital Officer". Paris....
- [10] Novartis AG. (12/21/18). "Press Release: Novartis Successfully Completes Acquisition of Endocyte". Basel....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top